Cargando…

Correction: Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma: an EBMT survey

Detalles Bibliográficos
Autores principales:	Sellner, Leopold, Schetelig, Johannes, Koster, Linda, Choi, Goda, Blaise, Didier, Beelen, Dietrich, Schianca, Fabrizio Carnevale, Passweg, Jakob, Schanz, Urs, Gyan, Emmanuel, Sora, Federica, Kröger, Nicolaus, Wulf, Gerald. G., Van Gorkom, Gwendolyn, Mayer, Jiri, Orvain, Corentin, Bourhis, Jean Henri, Jindra, Pavel, Potter, Victoria, Zallio, Francesco, Vandenberghe, Elisabeth, Robinson, Stephen, Hayden, Patrick J., Yakoub-Agha, Ibrahim, Montoto, Silvia, Dreger, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8636245/ https://www.ncbi.nlm.nih.gov/pubmed/34621022 http://dx.doi.org/10.1038/s41409-021-01490-9

Ejemplares similares

Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma: an EBMT survey
por: Sellner, Leopold, et al.
Publicado: (2020)

Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party
por: Schetelig, Johannes, et al.
Publicado: (2020)

Correction to: Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party
por: Schetelig, Johannes, et al.
Publicado: (2021)

The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-T’s come into focus
por: Passweg, Jakob R., et al.
Publicado: (2020)

The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies
por: Passweg, Jakob R., et al.
Publicado: (2019)

Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT
por: Pavlů, Jiří, et al.
Publicado: (2019)

Allogeneic stem cell transplantation for AML patients with RUNX1 mutation in first complete remission: a study on behalf of the acute leukemia working party of the EBMT
por: Waidhauser, Johanna, et al.
Publicado: (2021)

Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years
por: Passweg, Jakob R., et al.
Publicado: (2021)

Unrelated donor versus matched sibling donor in adults with acute myeloid leukemia in first relapse: an ALWP-EBMT study
por: Ruggeri, Annalisa, et al.
Publicado: (2016)

Outcomes and toxicity of allogeneic hematopoietic cell transplantation in chronic myeloid leukemia patients previously treated with second-generation tyrosine kinase inhibitors: a prospective non-interventional study from the Chronic Malignancy Working Party of the EBMT
por: Masouridi-Levrat, Stavroula, et al.
Publicado: (2021)

Allogeneic hematopoietic cell transplant for hairy cell leukemia: EBMT experience
por: Chihara, Dai, et al.
Publicado: (2022)

Severe cytopenia after CD19 CAR T-cell therapy: a retrospective study from the EBMT Transplant Complications Working Party
por: Penack, Olaf, et al.
Publicado: (2023)

Autologous hematopoietic cell transplantation for relapsed multiple myeloma performed with cells procured after previous transplantation–study on behalf of CMWP of the EBMT
por: Drozd-Sokołowska, Joanna, et al.
Publicado: (2022)

The European landscape on allogeneic haematopoeietic cell transplantation in Chronic Lymphocytic Leukaemia between 2009 and 2019: a perspective from the Chronic Malignancies Working Party of the EBMT
por: Tournilhac, Olivier, et al.
Publicado: (2023)

Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT
por: Kröger, Nicolaus, et al.
Publicado: (2021)

Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party
por: Penack, Olaf, et al.
Publicado: (2023)

Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)
por: Snowden, John A., et al.
Publicado: (2019)

Correction: Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)
por: Snowden, John A., et al.
Publicado: (2019)

The first steps towards a diverse and inclusive EBMT: a position paper
por: Montoto, S., et al.
Publicado: (2022)

Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: a report from the EBMT activity survey
por: Passweg, Jakob R., et al.
Publicado: (2022)

The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy
por: Ljungman, Per, et al.
Publicado: (2020)

Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation
por: Gagelmann, Nico, et al.
Publicado: (2019)

Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party
por: Hayden, Patrick J., et al.
Publicado: (2021)

Correction: The challenge of COVID-19 and hematopoietic cell transplantation: EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy
por: Ljungman, Per, et al.
Publicado: (2020)

Idelalisib for the Treatment of Chronic Lymphocytic Leukemia
por: Khan, Maliha, et al.
Publicado: (2014)

Idelalisib: a rare cause of enterocolitis
por: Balagoni, Harika, et al.
Publicado: (2016)

Association of pre-existing comorbidities with outcome of allogeneic hematopoietic cell transplantation. A retrospective analysis from the EBMT
por: Penack, Olaf, et al.
Publicado: (2021)

Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file study
por: Greinix, Hildegard T., et al.
Publicado: (2021)

Allogeneic hematopoietic cell transplantation in patients with chronic phase chronic myeloid leukemia in the era of third generation tyrosine kinase inhibitors: A retrospective study by the chronic malignancies working party of the EBMT
por: Chalandon, Yves, et al.
Publicado: (2022)

Comparison of outcomes for HLA-matched sibling and haplo-identical donors in Myelodysplastic syndromes: report from the chronic malignancies working party of EBMT
por: Raj, Kavita, et al.
Publicado: (2022)

Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)
por: Yakoub-Agha, Ibrahim, et al.
Publicado: (2020)

P1444: IMPACT OF CO-MORBIDITIES ON NON-RELAPSE MORTALITY AND CYTOKINE-RELEASE SYNDROME AFTER CD19 CAR-T CELL THERAPY - A RETROSPECTIVE STUDY FROM THE TCWP OF THE EBMT AND GOCART COALITION
por: Basak, G., et al.
Publicado: (2022)

Analysis of data collected in the European Society for Blood and Marrow Transplantation (EBMT) Registry on a cohort of lymphoma patients receiving plerixafor
por: Sureda, Anna, et al.
Publicado: (2019)

Primary Cancer Matters in Therapy-related Myeloid Neoplasm Patients Receiving Allogeneic Hematopoietic Cell Transplantation: A Study From the Chronic Malignancies Working Party of the EBMT
por: Robin, Marie, et al.
Publicado: (2023)

Measurable residual disease status and outcome of transplant in acute myeloid leukemia in second complete remission: a study by the acute leukemia working party of the EBMT
por: Gilleece, Maria H., et al.
Publicado: (2021)

Crystal structure of idelalisib tert-butanol monosolvate dihydrate
por: Nerdinger, Sven, et al.
Publicado: (2019)

Physicians Abstracts: EBMT 2010
Publicado: (2010)

Publication only: EBMT 2010
Publicado: (2010)

Current incidence, severity, and management of veno-occlusive disease/sinusoidal obstruction syndrome in adult allogeneic HSCT recipients: an EBMT Transplant Complications Working Party study
por: Ruutu, Tapani, et al.
Publicado: (2023)

Ex vivo and in vivo T cell-depleted allogeneic stem cell transplantation in patients with acute myeloid leukemia in first complete remission resulted in similar overall survival: on behalf of the ALWP of the EBMT and the MSKCC
por: Malard, Florent, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_8p02fd6006gbuo3jhmnro11svh